Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539658 | 0.91 | PPARD (0.47) | PPARDHDAC8NR4A2 | |
| SCHEMBL6539566 | 0.88 | PPARD (0.41) | PPARDHDAC8NR4A2 | |
| SCHEMBL6540595 | 0.88 | HDAC8 (0.47) | PPARDHDAC8ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6539420 | 0.86 | HDAC8 (0.50) | PPARDHDAC8ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6538965 | 0.83 | HDAC8 (0.45) | PPARDHDAC8ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6539893 | 0.83 | PPARD (0.42) | PPARDHDAC8ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6539128 | 0.83 | PPARD (0.42) | PPARDHDAC8ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6538820 | 0.82 | PPARD (0.48) | PPARDHDAC8ALDH1A1HTTNR4A2 | |
| SCHEMBL6539901 | 0.81 | PPARD (0.44) | PPARDNR4A2 | |
| SCHEMBL6539192 | 0.80 | PPARD (0.51) | PPARDALDH1A1HPGDNR4A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885HDAC8 1098/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.